Patients with wet age-related macular degeneration who responded well to rAAV.sFLT-1 subretinal gene therapy at 1 year maintained that response through 3 years, but the existence of a biologic efficacy signal was unable to be confirmed.
Researchers assessed the safety and 3-year results of rAAV.sFLT-1 gene therapy in combined phase 1 and 2a randomized controlled trials for wet AMD. The trials included 13 patients in a control group and 24 patients in a gene therapy group. All patients received intravitreal ranibizumab 0.5 mg in the study eye at baseline and (Read more...)
Uncategorized